| Differential metabolic effects of rosuvastatin and pravastatin in hypercholesterolemic patients. | |
| | |
MedLine Citation:
|
PMID: 22204857 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
BACKGROUND: Rosuvastatin and pravastatin have differential hydrophilicity and potency to inhibit hydroxymethylglutaryl-CoA reductase that may be relevant to changes in adiponectin levels, insulin resistance, and the rate of new onset diabetes in large clinical studies. Therefore, we hypothesized that rosuvastatin and pravastatin may have differential metabolic effects in hypercholesterolemic patients. METHODS: This was a randomized, single-blind, placebo-controlled, parallel study. Age, gender, and body mass index were matched. Fifty-four patients were given placebo, rosuvastatin 10mg, or pravastatin 40mg, respectively once daily for 2months. RESULTS: When compared with pravastatin therapy, rosuvastatin therapy significantly reduced total, LDL cholesterol, and apolipoprotein B levels (P<0.05 by post-hoc comparison), but comparably improved flow-mediated dilation after 2months. Interestingly, rosuvastatin therapy significantly increased fasting insulin (mean % changes; 28%, P=0.005). and HbA1c (1%, P=0.038) while decreasing plasma adiponectin levels (9%, P=0.010) and insulin sensitivity (assessed by QUICKI; 2%, P=0.007) when compared with baseline. By contrast, pravastatin therapy significantly decreased fasting insulin (8%, P=0.042), and HbA1c levels (1%, P=0.019) while increasing plasma adiponectin levels (36%, P=0.006) and insulin sensitivity (3%, P=0.005) when compared with baseline. Moreover, these differential effects were evident when outcomes of rosuvastatin and pravastatin therapy were directly compared (P=0.002 for insulin levels by ANOVA on Ranks, P=0.003 for adiponectin, P=0.003 for QUICKI, and P=0.010 for HbA1c by ANOVA). CONCLUSIONS: While significantly reducing lipoprotein profiles, rosuvastatin therapy had unwanted metabolic effects in hypercholesterolemic patients when compared with pravastatin therapy, that may be clinically relevant in patients prone to metabolic diseases. |
| | |
Authors:
|
Kwang Kon Koh; Michael J Quon; Ichiro Sakuma; Seung Hwan Han; Hanul Choi; Kyounghoon Lee; Eak Kyun Shin |
Related Documents
:
|
22170727 - Does rimonabant independently affect free fatty acid and glucose metabolism? 10737867 - Deferred imitation of object-related actions in human-reared juvenile chimpanzees and o... 8733657 - An investigation into the effects of british summer time on road traffic accident casua... 14594247 - Corn silage management: effects of hybrid, maturity, chop length, and mechanical proces... 9555917 - The bacillus subtilis gale gene is essential in the presence of glucose and galactose. 8603767 - Hepatic glucose production is regulated both by direct hepatic and extrahepatic effects... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-12-26 |
Journal Detail:
|
Title: International journal of cardiology Volume: - ISSN: 1874-1754 ISO Abbreviation: - Publication Date: 2011 Dec |
Date Detail:
|
Created Date: 2011-12-29 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8200291 Medline TA: Int J Cardiol Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Copyright Information:
|
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved. |
Affiliation:
|
Cardiology, Gil Medical Center, Gachon University, Incheon, Republic of Korea. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The obesity paradox in heart failure: Is etiology a key factor?
Next Document: Complex aortic atheroma plaques: study of 71 patients with lacunar infarcts.